Literature DB >> 24188676

An update on the use of antibodies against the filoviruses.

Erica Ollmann Saphire1.   

Abstract

Multiple recent, independent studies have confirmed that passively administered antibodies can provide effective postexposure therapy in nonhuman primates after exposure to an otherwise lethal dose of Ebola virus or Marburg virus. In this article, we review composition and performance of the antibody cocktails tested thus far, what is known about antibody epitopes on the viral glycoprotein target and ongoing research questions in further development of such cocktails for pre-exposure or emergency postexposure use.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24188676      PMCID： PMC4465755          DOI： 10.2217/imt.13.124

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


  79 in total

1.  Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.

Authors:  Paul W H I Parren; Tom W Geisbert; Toshiaki Maruyama; Peter B Jahrling; Dennis R Burton
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

Authors:  Larry Zeitlin; James Pettitt; Corinne Scully; Natasha Bohorova; Do Kim; Michael Pauly; Andrew Hiatt; Long Ngo; Herta Steinkellner; Kevin J Whaley; Gene G Olinger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

3.  Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.

Authors:  Z Y Yang; H J Duckers; N J Sullivan; A Sanchez; E G Nabel; G J Nabel
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

4.  Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain.

Authors:  W Weissenhorn; A Carfí; K H Lee; J J Skehel; D C Wiley
Journal:  Mol Cell       Date:  1998-11       Impact factor: 17.970

5.  Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change.

Authors:  Matthew Brecher; Kathryn L Schornberg; Sue E Delos; Marnie L Fusco; Erica Ollmann Saphire; Judith M White
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

6.  Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.

Authors:  Kartik Chandran; Nancy J Sullivan; Ute Felbor; Sean P Whelan; James M Cunningham
Journal:  Science       Date:  2005-04-14       Impact factor: 47.728

7.  Fruit bats as reservoirs of Ebola virus.

Authors:  Eric M Leroy; Brice Kumulungui; Xavier Pourrut; Pierre Rouquet; Alexandre Hassanin; Philippe Yaba; André Délicat; Janusz T Paweska; Jean-Paul Gonzalez; Robert Swanepoel
Journal:  Nature       Date:  2005-12-01       Impact factor: 49.962

8.  Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques.

Authors:  Gene Garrard Olinger; James Pettitt; Do Kim; Cara Working; Ognian Bohorov; Barry Bratcher; Ernie Hiatt; Steven D Hume; Ashley K Johnson; Josh Morton; Michael Pauly; Kevin J Whaley; Calli M Lear; Julia E Biggins; Corinne Scully; Lisa Hensley; Larry Zeitlin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-15       Impact factor: 11.205

9.  Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail.

Authors:  James Pettitt; Larry Zeitlin; Do H Kim; Cara Working; Joshua C Johnson; Ognian Bohorov; Barry Bratcher; Ernie Hiatt; Steven D Hume; Ashley K Johnson; Josh Morton; Michael H Pauly; Kevin J Whaley; Michael F Ingram; Ashley Zovanyi; Megan Heinrich; Ashley Piper; Justine Zelko; Gene G Olinger
Journal:  Sci Transl Med       Date:  2013-08-21       Impact factor: 17.956

10.  Niemann-Pick C1 (NPC1)/NPC1-like1 chimeras define sequences critical for NPC1's function as a flovirus entry receptor.

Authors:  Anuja Krishnan; Emily Happy Miller; Andrew S Herbert; Melinda Ng; Esther Ndungo; Sean P Whelan; John M Dye; Kartik Chandran
Journal:  Viruses       Date:  2012-10-25       Impact factor: 5.048
View more
  19 in total

1.  Mechanism of human antibody-mediated neutralization of Marburg virus.

Authors:  Andrew I Flyak; Philipp A Ilinykh; Charles D Murin; Tania Garron; Xiaoli Shen; Marnie L Fusco; Takao Hashiguchi; Zachary A Bornholdt; James C Slaughter; Gopal Sapparapu; Curtis Klages; Thomas G Ksiazek; Andrew B Ward; Erica Ollmann Saphire; Alexander Bukreyev; James E Crowe
Journal:  Cell       Date:  2015-02-26       Impact factor: 41.582

2.  Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies.

Authors:  Edgar Davidson; Christopher Bryan; Rachel H Fong; Trevor Barnes; Jennifer M Pfaff; Manu Mabila; Joseph B Rucker; Benjamin J Doranz
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

3.  Structural and Functional Studies on the Marburg Virus GP2 Fusion Loop.

Authors:  Nina Liu; Yisong Tao; Michael D Brenowitz; Mark E Girvin; Jonathan R Lai
Journal:  J Infect Dis       Date:  2015-03-18       Impact factor: 5.226

4.  Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia.

Authors:  Alexander Gutfraind; Lauren Ancel Meyers
Journal:  J Infect Dis       Date:  2015-01-29       Impact factor: 5.226

5.  Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.

Authors:  Frederick W Holtsberg; Sergey Shulenin; Hong Vu; Katie A Howell; Sonal J Patel; Bronwyn Gunn; Marcus Karim; Jonathan R Lai; Julia C Frei; Elisabeth K Nyakatura; Larry Zeitlin; Robin Douglas; Marnie L Fusco; Jeffrey W Froude; Erica Ollmann Saphire; Andrew S Herbert; Ariel S Wirchnianski; Calli M Lear-Rooney; Galit Alter; John M Dye; Pamela J Glass; Kelly L Warfield; M Javad Aman
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

6.  Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.

Authors:  Zhen-Yong Keck; Sven G Enterlein; Katie A Howell; Hong Vu; Sergey Shulenin; Kelly L Warfield; Jeffrey W Froude; Nazli Araghi; Robin Douglas; Julia Biggins; Calli M Lear-Rooney; Ariel S Wirchnianski; Patrick Lau; Yong Wang; Andrew S Herbert; John M Dye; Pamela J Glass; Frederick W Holtsberg; Steven K H Foung; M Javad Aman
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

7.  Structures of protective antibodies reveal sites of vulnerability on Ebola virus.

Authors:  Charles D Murin; Marnie L Fusco; Zachary A Bornholdt; Xiangguo Qiu; Gene G Olinger; Larry Zeitlin; Gary P Kobinger; Andrew B Ward; Erica Ollmann Saphire
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

8.  Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.

Authors:  Kang Yiu Lai; Wing Yiu George Ng; Fan Fanny Cheng
Journal:  Infect Dis Poverty       Date:  2014-11-28       Impact factor: 4.520

9.  Chemical and Structural Aspects of Ebola Virus Entry Inhibitors.

Authors:  Elisabeth K Nyakatura; Julia C Frei; Jonathan R Lai
Journal:  ACS Infect Dis       Date:  2014-12-18       Impact factor: 5.084

10.  Interferon-Induced Transmembrane Protein-Mediated Inhibition of Host Cell Entry of Ebolaviruses.

Authors:  Florian Wrensch; Christina B Karsten; Kerstin Gnirß; Markus Hoffmann; Kai Lu; Ayato Takada; Michael Winkler; Graham Simmons; Stefan Pöhlmann
Journal:  J Infect Dis       Date:  2015-06-01       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.